CD27 and B-cell non-Hodgkin lymphoma: In addition to combination with checkpoint inhibitor therapy, the combination of anti-CD20 and CD27 agonizing monoclonal antibodies has been investigated in an immunocompetent murine B-cell lymphoma and B-chronic lymphocytic leukemia models with a 100% tumor remission rate noted at 100 days (70).